Wilson Disease: Diagnosis and Treatment
Wilson disease (WD) is an autosomal recessive disorder of copper metabolism caused by mutations in the ATP7B gene (chromosome 13), which encodes a copper-transporting ATPase in hepatocytes. Loss of function leads to impaired biliary copper excretion and reduced ceruloplasmin incorporation, resulting in copper accumulation in the liver, brain (particularly the basal ganglia), cornea, and other organs. Prevalence is approximately 1 in 30,000 worldwide, with a carrier frequency of ~1 in 90. This article summarizes the neurological features, diagnostic approach, and treatment recommendations based on the AASLD Practice Guidance (Schilsky et al., 2023) and the EASL-ERN Clinical Practice Guidelines (2024).
Bottom Line
- Suspect WD in any patient with unexplained liver disease (regardless of age), liver disease with neuropsychiatric symptoms, or acute liver failure with Coombs-negative hemolysis
- No single gold standard test — diagnosis requires a combination of ceruloplasmin, 24h urine copper, Kayser-Fleischer rings, genetic testing, and liver biopsy
- Neurological WD: Dysarthria (91%), dystonia (69%), parkinsonism (rigidity 66%, bradykinesia 58%), tremor, chorea (16%), ataxia (28%)
- Treatment: Chelation (D-penicillamine or trientine) for symptomatic disease; zinc for asymptomatic patients or maintenance; lifelong therapy required
- Paradoxical neurological worsening occurs in 10–50% of neurological WD patients on chelation (first 1–3 weeks); less common with trientine or zinc
- Acute liver failure: Nearly 100% mortality without liver transplantation
Neurological Manifestations
Neurological WD typically presents between ages 20–40 (range 6–72), later than hepatic WD. It is more common in males (60% vs 40%). Kayser-Fleischer rings are present in ~90% of patients with neurological manifestations.
Movement Disorder Spectrum
| Manifestation | Frequency | Key Features | Anatomical Correlate |
|---|---|---|---|
| Dysarthria | ~91% | Often the earliest neurological symptom; may progress to anarthria; mixed cerebellar-extrapyramidal type | Basal ganglia, cerebellum, brainstem |
| Dystonia | ~69% | Focal, segmental, or generalized; risus sardonicus (fixed grimace); oromandibular and cervical dystonia common; can cause severe disability | Putamen, globus pallidus |
| Parkinsonism | Rigidity 66%, bradykinesia 58%, resting tremor 5% | Rigidity and bradykinesia more common than resting tremor; typically levodopa-unresponsive; associated with nigrostriatal dopaminergic deficit | Substantia nigra, striatum |
| Tremor | Common | Multiple types: postural, intention/action, resting, wing-beating (proximal "flapping" tremor at arms held outstretched — classic for WD); action tremor relates to cerebellar involvement | Cerebellum (vermis/hemispheres), red nucleus, thalamus |
| Cerebellar signs | ~28% | Gait ataxia, limb ataxia, intention tremor, nystagmus | Cerebellum |
| Chorea | ~16% | Irregular, involuntary movements; may coexist with dystonia | Caudate, putamen |
| Athetosis | ~14% | Slow, writhing movements of distal extremities | Basal ganglia |
| Dysphagia | Common | Progressive; contributes to aspiration risk and weight loss | Brainstem, basal ganglia |
Psychiatric Manifestations
- May precede motor symptoms or occur in isolation
- Personality/behavioral changes: Irritability, disinhibition, impulsivity, emotional lability
- Depression and anxiety: Common; may be first presenting symptom
- Psychosis: Rare but reported; can mimic primary psychiatric illness
- Cognitive impairment: Executive dysfunction, processing speed reduction; frank dementia rare with treatment; mild memory/language impairment in children
- Academic/occupational decline: Often the first noticed change in younger patients
Brain MRI Findings
- "Face of the giant panda" sign: T2 hyperintensity in midbrain tegmentum surrounding hypointense red nuclei and substantia nigra — classic but found only in advanced neurological disease (absent in ~1/3 of patients)
- "Double panda sign": Additional T2 changes in the tegmentum of the pons
- Putaminal involvement: T2 hyperintensity in the putamen is the most common finding
- Other findings: Signal changes in caudate, thalamus, brainstem, cerebellum, subcortical white matter
- Brain MRI should be performed in all adult patients and children >10 years with confirmed WD (EASL 2024)
Diagnosis
No single gold standard test exists. Diagnosis requires a combination of clinical findings and laboratory investigations. The Leipzig scoring system integrates multiple parameters.
Diagnostic Tests
| Test | WD Finding | Key Caveats |
|---|---|---|
| Serum ceruloplasmin | <14 mg/dL (normal >20) | Poor predictive value alone; can be low in other conditions; normal ceruloplasmin does NOT exclude WD; very low (<5 mg/dL) more strongly suggestive |
| 24h urine copper | Symptomatic: >100 μg/24h (>1.6 μmol); Asymptomatic/children: >40 μg/24h (>0.6 μmol) | Reflects non-ceruloplasmin-bound copper; false positives in cholestatic liver disease |
| Kayser-Fleischer rings | Golden-brown copper deposits on Descemet membrane (slit-lamp or OCT) | Present in ~90% with neurological WD but absent in ~60% with hepatic-only presentation; not pathognomonic (can occur in cholestatic liver disease) |
| Hepatic copper content | >250 μg/g dry weight (symptomatic); >75 μg/g (asymptomatic) | Gold standard for hepatic copper; requires liver biopsy; sampling error in cirrhosis |
| ATP7B genetic testing | Two pathogenic variants (782 variants identified; 216 likely pathogenic) | Not required for diagnosis but confirms in indeterminate cases; essential for family screening |
| Sunflower cataracts | Thin, centralized anterior capsular opacity with ray-like projections | 1.2% prevalence; reversible with treatment; does not affect visual acuity |
When to Suspect Wilson Disease
- Liver abnormalities of uncertain cause — regardless of age
- Unexplained liver disease associated with neurological or psychiatric disorder(s)
- Acute liver failure with Coombs-negative hemolytic anemia
- Recurrent self-limited nonimmune hemolysis
- Young-onset parkinsonism, dystonia, or wing-beating tremor
- Unexplained psychiatric symptoms in a young person with liver enzyme abnormalities
Acute Liver Failure Indicators
- Alkaline phosphatase : total bilirubin ratio <1:4
- AST : ALT ratio >2.2
- Coombs-negative intravascular hemolysis
- Coagulopathy, ascites, progressive encephalopathy
Treatment
Lifelong treatment is required. Discontinuation leads to symptom recurrence, liver failure, and potential need for transplantation.
Initial Therapy for Symptomatic Patients
| Agent | Mechanism | Initial Dose | Maintenance Dose | Key Notes |
|---|---|---|---|---|
| D-Penicillamine | Copper chelation (promotes urinary excretion) | Start 250–500 mg/day, increase by 250 mg every 4–7 days to 1000–1500 mg/day (15–20 mg/kg/day, max 2000 mg) in 2–4 divided doses | 750–1000 mg/day (10–15 mg/kg/day) in 2 divided doses | Take on empty stomach (food reduces absorption 50%); requires pyridoxine 25–50 mg/day; paradoxical neurological worsening in 10–50% (first 1–3 weeks); early sensitivity reactions (fever, rash, neutropenia, proteinuria) |
| Trientine | Copper chelation (promotes urinary excretion) | 20 mg/kg/day (max 2000 mg) in 2–3 divided doses, increase over 2–3 weeks | 10–15 mg/kg/day in 2–3 divided doses | Fewer adverse effects than D-penicillamine; paradoxical worsening less common; take with ample fluid; trientine tetrahydrochloride approved by FDA in 2022 (first new WD drug in >50 years); EASL 2024 suggests first-line for neurological WD |
Asymptomatic Patients / Maintenance Therapy
| Agent | Dose | Key Notes |
|---|---|---|
| Zinc (AASLD first-line for asymptomatic) | Adults/children >50 kg: 150 mg/day in 3 divided doses; 5–50 kg: 75 mg/day; <5 kg: 50 mg/day | Induces intestinal metallothionein to block copper absorption; well tolerated; paradoxical worsening uncommon; advantageous in renal impairment; take on empty stomach; concern: higher hepatic treatment failure rate than chelators in one study (14/88 vs 4/313) |
| Low-dose chelator | D-penicillamine or trientine at maintenance doses | Transition after >1 year of successful initial therapy with clinical/biochemical stability |
Monitoring
| Parameter | Target |
|---|---|
| 24h urine copper (initial chelation) | 1000–2000 μg/24h (16–32 μmol) — indicates adequate mobilization |
| 24h urine copper (maintenance chelation) | 200–500 μg/24h (3–8 μmol) for D-penicillamine; 150–500 μg/24h for trientine |
| 24h urine copper (zinc/stable) | <100 μg/24h (<1.6 μmol) |
| Overtreatment signs | Anemia, neutropenia, elevated ferritin; disproportionately low urine copper (<100 on chelation; <20 on zinc) |
| Biannual assessment | Liver biochemistries, INR, CBC, urinalysis (especially for chelator users), serum copper and ceruloplasmin trends, neurological exam (UWDRS) |
Paradoxical Neurological Worsening
- Occurs in 10–50% of neurological WD patients starting chelation therapy (D-penicillamine > trientine > zinc)
- Typically within the first 1–3 weeks of treatment
- Mechanism: rapid copper mobilization from liver causes transient increase in free copper in blood, with secondary deposition in the brain
- Management (EASL 2024): Decrease chelator dose, slow the dose escalation, or switch treatment; some experts advocate starting with lower doses and slower titration for neurological WD
- Worsening may be irreversible in some patients
Liver Transplantation
- Acute liver failure: Nearly 100% mortality without transplant; ALF occurs in 3–5% of WD patients
- Prognostic scores: Nazer score and New Wilson Index help identify candidates
- Decompensated cirrhosis: Refractory to medical therapy
- Neurological disease: EASL 2024 now recognizes severe neurological symptoms as a valid transplant indication (broadening the therapeutic scope beyond liver failure alone)
- Post-transplant: copper metabolism normalizes (donor liver has functional ATP7B)
Pregnancy
- Anticopper therapy generally considered safe in pregnancy
- Do not discontinue treatment during pregnancy (risk of fulminant liver failure)
- Dose reduction may be appropriate, especially for D-penicillamine (teratogenic at high doses in animals)
- Zinc has the most favorable safety profile in pregnancy
- Spontaneous abortion rate 26% overall; significantly lower in treated vs untreated patients (OR 2.85)
- Patients with current/previous decompensated cirrhosis should avoid conception
Other Organ Involvement
| System | Manifestations |
|---|---|
| Hepatic | Asymptomatic transaminase elevation, chronic hepatitis, steatosis, cirrhosis (compensated/decompensated), ALF with hemolysis |
| Hematologic | Coombs-negative intravascular hemolysis (hallmark of WD ALF), thrombocytopenia, leukopenia (hypersplenism) |
| Renal | Nephrolithiasis, Fanconi syndrome, hypokalemia, hypouricemia |
| Skeletal | Osteoporosis, rickets-like changes, arthropathy, demineralization |
| Cardiac | Cardiomyopathy, arrhythmias, atrial fibrillation |
| Endocrine | Hypoparathyroidism, infertility, recurrent miscarriages |
Family Screening
- All first-degree relatives should be screened
- Genetic testing is the most efficient method when the proband's ATP7B mutations are identified
- If genetic testing unavailable: serum ceruloplasmin, 24h urine copper, slit-lamp examination, liver biochemistries
- Siblings of an affected individual have a 25% chance of having WD
- Early identification allows presymptomatic treatment, which prevents organ damage
Practical Treatment Algorithm
- Symptomatic hepatic WD: Chelation therapy (D-penicillamine or trientine) with transition to maintenance (lower-dose chelator or zinc) after >1 year of stability
- Symptomatic neurological WD: Chelation with trientine preferred (lower risk of paradoxical worsening); start low, titrate slowly; EASL 2024 suggests zinc as first-line alternative for neurological patients; adjunctive symptomatic treatment for dystonia, parkinsonism, tremor, psychiatric symptoms
- Asymptomatic WD (presymptomatic or stable): Zinc monotherapy (AASLD first-line) or low-dose chelation
- Acute liver failure: Urgent liver transplantation evaluation (mortality ~100% without)
- Pregnancy: Continue treatment (do not discontinue); zinc preferred; reduce D-penicillamine dose
- Lifelong monitoring: Biannual liver biochemistries, 24h urine copper, CBC, neurological assessment; watch for overtreatment and nonadherence
Novel Therapies Under Investigation
- ALXN1840 (bis-choline tetrathiomolybdate): Novel chelating agent with dual mechanism (intracellular detoxification and biliary excretion); phase 3 trials ongoing
- VTX-801 and UX701: Gene therapy candidates targeting hepatic ATP7B expression
References
- Schilsky ML, Roberts EA, Bronstein JM, et al. A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 Practice Guidance on Wilson disease from the American Association for the Study of Liver Diseases. Hepatology. 2023;77(4):1428-1455. doi: 10.1002/hep.32801
- EASL-ERN. Clinical Practice Guidelines on Wilson's disease. J Hepatol. 2025. doi: 10.1016/j.jhep.2024.11.007
- Czlonkowska A, Litwin T, Dusek P, et al. Wilson disease. Nat Rev Dis Primers. 2018;4(1):21. doi: 10.1038/s41572-018-0018-3